Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT phase 3 study of isatuximab + lenalidomide + dexamethasone with or without bortezomib in newly diagnosed transplant-ineligible non-frail elderly multiple myeloma
2024-517215-67-00Phase 3Authorised
- Sponsor
- CHU de Poitiers
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab, lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by CHU de Poitiers. Primary endpoint: MRD negative rate at 18 months. Planned start Jun 2021; status: authorised.
02
Drugs
isatuximablenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-517215-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517215-67-00.